The Medical Letter on Drugs and Therapeutics
Carbidopa/Levodopa Extended-Release Capsules (Rytary)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Carbidopa/Levodopa Extended-Release Capsules (Rytary)
The FDA has approved a new formulation of carbidopa/levodopa (Rytary – Impax) in extended-release capsules for treatment of Parkinson’s disease (PD).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Carbidopa/Levodopa Extended-Release Capsules (Rytary)
Article code: 1467a
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.